{"id":217616,"date":"2025-07-11T10:02:25","date_gmt":"2025-07-11T15:02:25","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2025\/07\/first-stem-cell-nerve-therapy-meant-to-reverse-paralysis-enters-clinical-trial"},"modified":"2025-07-11T10:02:25","modified_gmt":"2025-07-11T15:02:25","slug":"first-stem-cell-nerve-therapy-meant-to-reverse-paralysis-enters-clinical-trial","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2025\/07\/first-stem-cell-nerve-therapy-meant-to-reverse-paralysis-enters-clinical-trial","title":{"rendered":"First Stem Cell Nerve Therapy Meant to Reverse Paralysis Enters Clinical Trial"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/first-stem-cell-nerve-therapy-meant-to-reverse-paralysis-enters-clinical-trial.webp\"><\/a><\/p>\n<p>It begins with a fall, a crash, or a sudden jolt. In a split second, the spinal cord shatters. For millions, the damage is permanent. But in Shanghai and Suzhou, a group of scientists believes that might soon change.<\/p>\n<p>This May, a biotech startup named XellSmart Biopharmaceutical received rare dual approval from both U.S. and Chinese regulators to launch a Phase I trial for an experimental treatment. The therapy is designed to repair spinal cord injuries using neurons grown in a lab.<\/p>\n<p>The trial, described as the first of its kind, is being led by the Third Affiliated Hospital of Sun Yat-sen University in China. The goal: to test whether specialized nerve cells can be safely implanted into people whose spinal cords were recently injured.<\/p>\n<hr>\n<p>A cell therapy for regenerating broken spinal cord using lab-grown neurons enters human trials for the first time.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>It begins with a fall, a crash, or a sudden jolt. In a split second, the spinal cord shatters. For millions, the damage is permanent. But in Shanghai and Suzhou, a group of scientists believes that might soon change. This May, a biotech startup named XellSmart Biopharmaceutical received rare dual approval from both U.S. and [\u2026]<\/p>\n","protected":false},"author":534,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,47],"tags":[],"class_list":["post-217616","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-neuroscience"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/217616","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/534"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=217616"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/217616\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=217616"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=217616"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=217616"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}